ADAMTS9 and prostate carcinoma: Low expression of ADAMTS9-AS1 predicts poorer survival than higher ADAMTS9-AS1 expression in patients with prostate cancer, and ADAMTS9-AS1 inhibits prostate cancer cell proliferation, indicating that ADAMTS9-AS1 functions as a tumor suppressor in prostate cancer15.